[ad_1]
Pharmaceutical firm Merck & Co. Inc. (NYSE: MRK) reported a pointy fall in adjusted earnings for the fourth quarter of 2023, regardless of a modest improve in revenues.
Fourth-quarter worldwide gross sales elevated 6% year-over-year to $14.6 billion, primarily reflecting the sustained development throughout oncology and vaccines.
The corporate reported a internet lack of $1.23 billion or $0.48 per share for the December quarter, in comparison with a revenue of $3.02 billion or $1.18 per share within the prior-year interval. On an adjusted foundation, it was earnings of $0.03 per share in This autumn, down 98% from the fourth quarter of 2022.
“As we transfer ahead, I’m assured that our sturdy momentum will proceed, underpinned by the unwavering dedication of our gifted world group,” mentioned Merck’s CEO Robert Davis.
Prior Efficiency
[ad_2]
Source link
